-
01:09:06 AM

GILD - Gilead Sciences, Inc.

04/01/21 4:15 PM
Nasdaq : GILD
Kite Submits Supplemental Biologics License Application to U.S. Food and Drug Administration for Tecartus(R) in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Kite, a Gilead Company (Nasdaq: GILD), today announced that it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Tecartus (R) (brexucabtagene autoleucel) for the treatment of adult patients with relapsed or refractory B-cell precursor
RHEA-AI
neutral
03/25/21 4:01 PM
Nasdaq : GILD
European Medicines Agency Validates Marketing Authorization Application for Sacituzumab Govitecan-Hziy for the Treatment of Metastatic Triple-Negative Breast Cancer
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for sacituzumab govitecan-hziy (SG) for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast
RHEA-AI
neutral
03/15/21 6:45 AM
Nasdaq, NYSE : GILD, MRK
Gilead and Merck Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that they have entered into an agreement to co-develop and co-commercialize long-acting treatments in HIV that combine Gilead's investigational capsid inhibitor,
RHEA-AI
very positive